Catalyst Pharmaceuticals, Inc. (CPRX)

Catalyst Pharmaceuticals' stock price has been influenced by several events, including a positive Q3 2025 earnings report and raised revenue guidance, which led to a rise in premarket trading. The company announced a $200 million share repurchase program. Insider selling activity was observed by Molly Harper and Brian Elsbernd. The stock's 6-month performance showed a 2.21% increase.

Catalyst Pharmaceuticals has demonstrated sustained demand across its product portfolio, with strong demand for FIRDAPSE and AGAMREE, and steady revenue from FYCOMPA. This suggests consistent demand for its products rather than significant seasonality.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare neurological and neuromuscular diseases. Its major products include FIRDAPSE for Lambert–Eaton myasthenic syndrome (LEMS), AGAMREE for Duchenne muscular dystrophy (DMD), and FYCOMPA, an epilepsy drug.

Catalyst Pharmaceuticals is headquartered in Coral Gables, Florida, and has a strong U.S. presence. Firdapse is also approved for use in Europe, and the company is exploring opportunities to expand its global reach.

Catalyst Pharmaceuticals has received positive recognition, including being named one of North America's Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™, being recognized among BioSpace 2026 Best Places to Work, and receiving a ranking on Forbes' 2026 List of America's Most Successful Small-Cap Companies.

Catalyst Pharmaceuticals has significant institutional ownership, with 729 institutional owners holding a total of 126,963,307 shares. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, and State Street Corp. Biomarin Pharmaceutical Inc. is the largest individual shareholder, owning 5.42% of the company's shares.